Journal of Metabolic Syndrome

ISSN: 2167-0943

Open Access

Current Issue

Volume 8, Issue 2 (2019)

    Research Article Pages: 1 - 6

    Retinol Binding Protein 4: Possible Relation between Insulin Resistance in Type 2 Diabetes and Visceral Obesity

    Alyaa Ahmed  Elsherbeny, Emad Abdel Mohsen Abdel Hady, Amira Ramadan Elmahdi

    Introduction: Retinol Binding Protein 4 (RBP-4), an adipokine, that was identified as key regulator of obesity related insulin resistance and type 2 diabetes, and certain components of metabolic syndrome. Objectives: To study the relation of RBP4 and insulin resistance in patients with visceral obesity and type 2 diabetes mellitus. Patients and Methods: This study was conducted on 74 subjects; classified according to their Body Mass Index (BMI) and Waist Circumference (WC) into three main groups: Group 1: included 27 obese diabetic subjects Group 2: included 28 obese non diabetic subjects. Group 3: included 19 healthy non-obese subjects, serving as control. All patients were assessed for Insulin Resistance (IR) index by HOMA-IR and Assessment of B cell function by HOMA-β, RBP4. Results: RBP4 was significantly higher in group 1 and group 2 compared to group 3(p˃0.05) and was nonsignificant in group 1 compared to group 2. There was non-significant correlation between RBP4 & (anthropometric parameters, lipid profile, FBG, 2HPP, HBA1C, FI, HOMA-IR, HOMA-B) in group 1. RBP4 was significantly negative correlated with (BW, HDL) and significant positive correlated with FI, HOMA-IR in the group 2. In viscerally obese subjects HOMA-B% was lower than diabetes group and control group. Conclusion: RBP4 was correlated to insulin resistance in viscerally obese subjects. Viscerally obese subjects had impaired B cell function they are liable for type 2 diabetes and other metabolic risks

    Editorial Pages: 1 - 2

    Research Contribution and Achievement

    Annie Shergill

    Conference Series LLC fosters research excellence and leadership by recognizing the outstanding researchers, exceptional graduates or early academicians who have distinctive enthrallment towards the conference themes. Nominees are judged on past accomplishments, research excellence and outstanding academic achievements. Researchers throughout the world who have been credited with outstanding achievements can make a significant contribution to the advancement of their field, thereby having a positive influence on the society.

    Editorial Pages: 1 - 2

    2020 Market Analysis Editorial- Diabetes & Obesity 2020

    Dr. Mohamed Zaky

    Obesity and the related diabetes scourges speak to a genuine concern around the world. Bariatric/metabolic surgery rose in a years ago as a profitable helpful alternative for stoutness and related maladies, including type 2 diabetes mellitus (T2DM). The convoluted system of instruments associated with corpulence and T2DM have not totally characterized yet. There is as yet a level-headed discussion on which would be the primary metabolic deformity prompting metabolic crumbling: insulin protection or hyperinsulinemia? Knowledge into the metabolic impacts of bariatric/metabolic surgery has uncovered that, past weight reduction and nourishment confinement, different instruments can be enacted by the improvements of the gastrointestinal tract, for example, the incretin/hostile to incretin framework, changes in bile corrosive creation and stream, and adjustments of gut miniaturized scale biota; every one of them conceivably associated with the abatement of T2DM. The entire clarification of these systems will prompt a superior comprehension of the pathogenesis of this illness. Our point was to audit a portion of the metabolic instruments engaged in the advancement of T2DM in corpulent patients and additionally in the abatement of this condition in patients submitted to bariatric/metabolic surgery.

    Editorial Pages: 1 - 2

    2020 Awards Editorial- Diabetes & Obesity 2020

    Dr. Mohamed Zaky 

    The organizing committee members of  Annual Congress on Diabetes, Metabolism, and Obesity have finally revealed the theme for  this year`s Diabetes & Obesity 2020 Conference and it’s going to be Reunite and raise hands against the Metabolic disorders. Conference Series  and the organizing committee of Diabetes & Obesity 2020 acknowledges the efforts and contribution of scholars, researchers, academicians, and scientists in the field of Diabetes & Endocrinology and has decided to introduce various achievement awards for all the participants. Diabetes & Obesity 2020 conference will offer various awards to outstanding researchers, scientists, exceptional graduates or early academicians who have a notable contribution to the field and possess keen interest towards the conference theme. The awards strive in providing a strong professional development opportunity for all researchers at different levels of their careers. Moreover our conferences will provide a much needed time and space for all to interact with colleagues from different parts of the world   and to create long lasting networks and relations. 

    Editorial Pages: 1 - 1

    2020 Conference Announcement Editorial- Diabetes & Obesity 2020

    Dr. Mohamed Zaky 

    The “11th World Congress on Endocrinology and Metabolic Disorders” hosted by conference series with the theme, “Exploring Novel Aspects in Endocrinology and Metabolic Disorders” was successfully executed during September 3-4, 2018 in Auckland, New Zealand. The conference offered a unique opportunity to investigators across the globe in order to meet, explore, network and perceive new scientific innovations. The conference received commendable and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the global scientists, Professors, Academicians, Researcher Scholars and students  from  diverse fields of Diabetes & Endocrinology

    Research Article Pages: 1 - 5

    Transdermal or Endogenous Testosterone in Men with Androgen Deficiency Syndrome and Type 2 Diabetes Mellitus?

    Mitko D Mitkov, Presiyana V Nyagolova

    Objective: To compare the effect of Transdermal Testosterone (TT) or Clomiphene Citrate (CC) administration on metabolic control, erectile function and quality of life in patients with T2DM.
    Materials and patients: The study population included 40 men with T2DM up to 60 years old, who were on metformin monotherapy at doses up to 2550 mg daily over the last three months. The patients had total testosterone values between 8 and 12 nmol/L and LH levels within the normal range. Other causes of hypogonadism were excluded. The patients were asked to answer the IIEF and the SF-36 surveys. BMI, WC, lipid profile, HbA1c, testosterone, SHBG, LH, FSH, PSA, and albuminuria were monitored at their initial visits, and on the 12th and the 24th weeks. 19 of the patients were treated with TT and 21 with CC.
    Results: Both groups corresponded in age, BMI, and HbA1c. Three-month administration of TT resulted in a significant increase of serum T and SHBG levels, and a reduction in BMI, HbA1c, WC, TC, TG, that extended to the 6th month. In the group treated with CC the monitored parameters showed the same dynamics.
    In the group treated with TT we found significant improvement in all indicators of IIEF at the 3rd month. At the 6th month of and the overall satisfaction declined. In patients treated with CC it was found a significant improvement in all domains during the follow-up period, but without reaching statistical significance. We found significant improvement in physical (p<0.001) and mental (p<0.01) health and in quality of life (p<0.01) at the 3rd month, that extended until the 6th month.
    Conclusions: The on time initiation of treatment, that increases testosterone levels, is essential for the metabolic disorders, erectile dysfunction and quality of life. Trials of a longer duration are required to establish the benefits and risks of that therapy in patients with T2DM and Androgen Deficiency Syndrome.

    Editorial Pages: 1 - 4

    2020 Market Analysis of International Conference on Digestive and Metabolic Diseases

    Annie Shergill 

    Digestive Diseases is the branch of medicine Related to the GI tract (stomach and intestines) and the accessory organs of digestion (from the mouth to the anus) focused on the digestive system and its disorders. Some of the conditions treated under this specialty include but are not limited to: Crohn’s disease, Gastroesophageal reflux disease (GERD), inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, colon cancer, heartburn, gastric cancer, diverticulitis, and ulcerative colitis. Intestinal problems, such as polyps and cancer, infections, celiac disease, Crohn disease, ulcerative colitis, diverticulitis, malabsorption, short bowel syndrome, and intestinal ischemia. Gastroesophageal reflux disease (GERD), peptic ulcer disease, and hiatal hernia. 

    Young Research Forum Pages: 1 - 2

    Young Researchers Forum - Young Scientist Awards Diabetes and Obesity 2020

    Dr. Mohamed Zaky

    Diabetes and Obesity 2020 is together individuals in the scholarly community and society keen on Diabetes and Obesity to share the most recent patterns and imperative issues important to our knowledge.

    Young Research Forum Pages: 1 - 2

    Young Researchers Forum - Young Scientist Awards Metabolic Diseases Meet 2020

    Dr. Gerald C

    Share this article

    Prestigious Award for Young Research’s at Metabolic Diseases Meet 2020- Discovering New Exploration in endocrinology and oncology field Metabolic Diseases Conference Committee is glad to announce 2nd International Metabolic Diseases and Liver Cancer Conference during December 07-08, 2020 in Dubai, UAE. Metabolic Diseases Meet 2020 developments are maintaining their momentum. Metabolic Conference program delves into strategic discussions.

    Volume 9, Issue 1 (2020)

      2021 Conference Announcement Pages: 1 - 2

      Protecting the World from Metabolic diseases- Metabolic Diseases Meet 2020

      Gerald C Hsu*

      Metabolic disease meet in Dubai is a prominent conference with its best scientific programs that includes Oral presentations, Poster presentations, Symposiums, Workshops, Exhibitions that helps to explain the latest advancements in the field of metabolic diseases and cancer to the audience.

      Research Article Pages: 1 - 11

      Aerobic Glycolysis Couples Metabolic Syndrome to Alzheimer's Disease

      Delia Labatt, Cole Smith and Kelly Gibas*

      Alzheimer's Disease (AD) is a global epidemic; every 3 seconds someone in the world develops dementia. An estimated 50 million people are living with a disease that cannot be prevented, treated or cured. Without novel breakthroughs, AD is predicted to exceed 130 million by 2050. Pharmaceuticals offer minimal relief with dismal evidence of reversing neurodegeneration. Research focuses on β-amyloid plaques and tau tangles; but, in a clinical trial, medications designed to sop-up toxic proteins in the brain fail to impede neural decline. Instead, plaques and tangles appear to be late-arrivers in the insidious progression of dementia. The recent explosion of comorbid metabolic pathologies (global prevalence of T2DM estimated @ 463 million) invites researchers into a deeper discussion of bioenergetics regulating cognitive impairment and metabolic dysregulation. Age-related energy deficits, driven by peripheral insulin resistance, exacerbate Aβ/tau accumulation, increase oxidative stress and impede mitochondrial function; work by Sergi et al. and Mastroeni et al. suggest that mitochondrial dysfunction with epigenetic impairment in oxidative respiration appear to be the earliest offenders in the progression of T2DM and AD . This case report highlights a novel, integrated intervention with a 69-year-old male dually diagnosed with T2DM and Mild Cognitive Impairment (MCI). Physiological biomarkers were measured pre/mid/post-intervention; the MoCA (Montreal Cognitive Assessment) measured cognitive function, pre/post. Statistically significant results were observed in the metabolic risk biomarkers, memory was restored to normal ranges, and the HbA1c normalized out of the diabetic range @ <5.6%. Furthermore, the metabolic and cognitive improvements were sustained @ 3 months postintervention. These promising results suggest that dietary ketogenesis restores peripheral insulin sensitivity, mitigates T2DM and improves cognition by circumventing neural starvation via the restoration of metabolic flexibility.

      Research Article Pages: 1 - 12

      Association of Vitamin D Status with Metabolic Syndrome and its Components in Bangladeshi Urban Women

      Mridha Fatima Cohra, Mahrima Parveen, Tasnin Akter Nila, Soheli Alam and Zakir Hossain Howlader*

      Background: The prevalence of metabolic syndrome is on the rise in developing countries like Bangladesh along with decreasing Vitamin D levels. As women are more vulnerable to metabolic syndrome and vitamin D deficiency, and connection among these were reported in various population, this research aims to quantify the association between vitamin D and metabolic syndrome and its components among Bangladeshi women from urban area.

      Methods: Necessary data were collected from 233 participants over five months from 2015 to 2016 in Dhaka, Bangladesh. The concentration of Triglyceride, High- Density Lipoprotein (HDL) levels, fasting plasma glucose was measured with kits and vitamin D analysis was performed using High-Performance Liquid Chromatography.

      Results: In this study, the prevalence of metabolic syndrome among the population was found to be 59.66%. When the subjects were divided into different quarters according to vitamin D sufficiency levels, subjects in all the quarters had significantly lower odds ratios of having metabolic syndrome compared to the lowest quarter.

      Conclusion: The number of metabolic syndrome components were found to be inversely correlated with Vitamin D level and individual components were found to be correlated with Vitamin D, indicating the inverse association between vitamin D and prevalence of risk of metabolic syndrome.

      Editor Note Pages: 1 - 2

      Editor note Journal of metabolic syndrome

      Olivia Bratt*

      I am pleased to mention that during the year 2019, all issues of volume 8 were published online well within the time and the print issues were also brought out and dispatched within 30 days of publishing the issue online. JMS also brought out an online special issue in 2019. JMS Published 7 research Article 5 editorial and 2 short communication 2019. In 2018 JMS Published 4 Research Article, 5 Review Article and 1 short communication. The H-index of the journal, however, increased to 10. During the calendar year 2019, Jms received a total of 28 papers, out of which 14 articles (50%) were rejected in the preliminary screening due to plagiarism or being out of the format. During 2019 around 20 articles were subjected to the peer-review process and 14 of those were accepted. In the 8 Volume 14 published during the year 2019, a total of 14 articles were published (at an average of 5 articles per issue) of which, 50 % articles were by foreign authors. A total of 5 research scientists from India and abroad reviewed the 10 articles published in volume 7. Average publication lag time of an article was further reduced to 6-8 weeks. I take this opportunity to acknowledge the contribution of Liang-Kung Chen,during the final editing of articles published and the support rendered by the editorial assistant, Olivia Bratt bringing out issues of JMS in time. I would also like to express my gratitude to all the authors, reviewers, the publisher, the advisory and the editorial board of JMS, the office bearers and staff of IPA secretariat for their support in bringing out yet another volume of JMS and look forward to their unrelenting support to bring out the Volume 8 of JMS in scheduled time.

    Relevant Topics

Google Scholar citation report
Citations: 506

Journal of Metabolic Syndrome received 506 citations as per Google Scholar report

Journal of Metabolic Syndrome peer review process verified at publons

Indexed In

arrow_upward arrow_upward